Sygnature Discovery loans key equipment to support UK Government’s COVID-19 testing strategy

Sygnature Group is supporting the Government’s COVID-19 testing strategy with the loan of a key piece of equipment. The machine, a Tecan Freedom EVO 100, will be used to help automate and accelerate the analysis of samples at the first of the UK Government’s new Lighthouse Labs in Milton Keynes.

Sygnature Discovery loans key equipment to support UK Government’s COVID-19 testing strategy
The Tecan Freedom EVO 100 in use at Sygnature Discovery's laboratories

The state-of-the-art liquid handling machine is designed to automate the pipetting of multiple samples in laboratories undertaking biological testing. The EVO 100 is considerably faster than manual pipetting, increasing the speed at which assays can be run and enhancing sample through-put. The equipment also facilitates better assay reproducibility and allows resources and testing equipment to be used more efficiently.

The Prime Minister’s Office approached Dr Simon Hirst, Sygnature’s Founder and CEO, just before Easter and arrangements were swiftly put in place for the Government to collect the EVO 100 on the morning of the 15th April 2020. At Sygnature the machine is normally used by the high-throughput chemistry group supporting the synthesis of the company’s corporate compound collection. Currently the chemical library work at Sygnature is suspended to focus resources on their client programs.

As well as supporting the UK Government’s COVID-19 testing efforts, Sygnature is putting its drug discovery know how to work to support the fight against the coronavirus.

We have a number of active programs working with UK-based academics. These include the design and synthesis of novel compounds against COVID-19 and the metabolic evaluation of potential drug-like molecules. We are also in discussions with charities and biotech companies about how we can apply our anti-viral drug discovery expertise. We have set up an in-house team of expert drug-hunters to contribute to solving this global pandemic."

Dr Simon Hirst, Sygnature’s Founder and CEO


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
The antiviral potential of 4′-fluorouridine as an oral treatment against RSV and SARS-CoV-2